Treatment of lung infection in patients with cystic fibrosis: current and future strategies

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Treatment of lung infection in patients with cystic fibrosis : current and future strategies. / Döring, Gerd; Flume, Patrick; Heijerman, Harry; Elborn, J Stuart; Consensus Study Group.

I: Journal of Cystic Fibrosis, Bind 11, Nr. 6, 12.2012, s. 461-479.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Döring, G, Flume, P, Heijerman, H, Elborn, JS & Consensus Study Group 2012, 'Treatment of lung infection in patients with cystic fibrosis: current and future strategies', Journal of Cystic Fibrosis, bind 11, nr. 6, s. 461-479. https://doi.org/10.1016/j.jcf.2012.10.004

APA

Döring, G., Flume, P., Heijerman, H., Elborn, J. S., & Consensus Study Group (2012). Treatment of lung infection in patients with cystic fibrosis: current and future strategies. Journal of Cystic Fibrosis, 11(6), 461-479. https://doi.org/10.1016/j.jcf.2012.10.004

Vancouver

Döring G, Flume P, Heijerman H, Elborn JS, Consensus Study Group. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. Journal of Cystic Fibrosis. 2012 dec;11(6):461-479. https://doi.org/10.1016/j.jcf.2012.10.004

Author

Döring, Gerd ; Flume, Patrick ; Heijerman, Harry ; Elborn, J Stuart ; Consensus Study Group. / Treatment of lung infection in patients with cystic fibrosis : current and future strategies. I: Journal of Cystic Fibrosis. 2012 ; Bind 11, Nr. 6. s. 461-479.

Bibtex

@article{97a48ac074554241bef8875d5893c99d,
title = "Treatment of lung infection in patients with cystic fibrosis: current and future strategies",
abstract = "In patients with cystic fibrosis (CF) lung damage secondary to chronic infection is the main cause of death. Treatment of lung disease to reduce the impact of infection, inflammation and subsequent lung injury is therefore of major importance. Here we discuss the present status of antibiotic therapy for the major pathogens in CF airways, including prophylaxis against infection, eradication of early infection, suppression of chronic infection, and the treatment of infective exacerbations. We outline measures to optimize maintenance treatment for infection in the light of novel antibiotic drug formulations. We discuss new developments in culture-independent microbiological diagnostic techniques and the use of tools for monitoring the success of antibiotic treatment courses. Finally, cost-effectiveness analyses for antibiotic treatment in CF patients are discussed.",
keywords = "Anti-Bacterial Agents, Cystic Fibrosis, Humans, Pneumonia, Bacterial, Pseudomonas Infections, Pseudomonas aeruginosa",
author = "Gerd D{\"o}ring and Patrick Flume and Harry Heijerman and Elborn, {J Stuart} and Niels H{\o}iby and {Consensus Study Group}",
note = "Copyright {\circledC} 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.",
year = "2012",
month = "12",
doi = "10.1016/j.jcf.2012.10.004",
language = "English",
volume = "11",
pages = "461--479",
journal = "Journal of Cystic Fibrosis",
issn = "1569-1993",
publisher = "Elsevier",
number = "6",

}

RIS

TY - JOUR

T1 - Treatment of lung infection in patients with cystic fibrosis

T2 - current and future strategies

AU - Döring, Gerd

AU - Flume, Patrick

AU - Heijerman, Harry

AU - Elborn, J Stuart

AU - Høiby, Niels

AU - Consensus Study Group

N1 - Copyright © 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

PY - 2012/12

Y1 - 2012/12

N2 - In patients with cystic fibrosis (CF) lung damage secondary to chronic infection is the main cause of death. Treatment of lung disease to reduce the impact of infection, inflammation and subsequent lung injury is therefore of major importance. Here we discuss the present status of antibiotic therapy for the major pathogens in CF airways, including prophylaxis against infection, eradication of early infection, suppression of chronic infection, and the treatment of infective exacerbations. We outline measures to optimize maintenance treatment for infection in the light of novel antibiotic drug formulations. We discuss new developments in culture-independent microbiological diagnostic techniques and the use of tools for monitoring the success of antibiotic treatment courses. Finally, cost-effectiveness analyses for antibiotic treatment in CF patients are discussed.

AB - In patients with cystic fibrosis (CF) lung damage secondary to chronic infection is the main cause of death. Treatment of lung disease to reduce the impact of infection, inflammation and subsequent lung injury is therefore of major importance. Here we discuss the present status of antibiotic therapy for the major pathogens in CF airways, including prophylaxis against infection, eradication of early infection, suppression of chronic infection, and the treatment of infective exacerbations. We outline measures to optimize maintenance treatment for infection in the light of novel antibiotic drug formulations. We discuss new developments in culture-independent microbiological diagnostic techniques and the use of tools for monitoring the success of antibiotic treatment courses. Finally, cost-effectiveness analyses for antibiotic treatment in CF patients are discussed.

KW - Anti-Bacterial Agents

KW - Cystic Fibrosis

KW - Humans

KW - Pneumonia, Bacterial

KW - Pseudomonas Infections

KW - Pseudomonas aeruginosa

U2 - 10.1016/j.jcf.2012.10.004

DO - 10.1016/j.jcf.2012.10.004

M3 - Journal article

VL - 11

SP - 461

EP - 479

JO - Journal of Cystic Fibrosis

JF - Journal of Cystic Fibrosis

SN - 1569-1993

IS - 6

ER -

ID: 49597767